首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal PLA1A Antibody

  • 中文名： PLA1A抗体
  • 别    名： Phospholipase A1 member A, 311-, Phosphatidylserine-specific phospholipase A1, PS-PLA1, PLA1A, NMD, PSPLA1
货号: IPDX30512
Price： ￥1180
数量：
大包装询价

验证与应用

应用及物种
WB 1/1000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesAw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A*68; HLA-A; MHC class I antigen HLA A heavy chain
Entrez GeneID3105
WB Predicted band sizeCalculated MW: 41 kDa; Observed MW: 41 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenThe antiserum was produced against synthesized peptide derived from human HLA Class I. AA range:204-253
FormulationPurified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol.

+ +

参考文献

以下是3篇与PLA1A抗体相关的文献摘要概览：

---

1. **文献名称**：*Autoantibody against phospholipase A1 member A as a novel biomarker for hepatocellular carcinoma*

**作者**：Kondo Y, et al.

**摘要**：该研究发现肝细胞癌(HCC)患者血清中抗PLA1A IgG抗体的水平显著升高，提示其可作为HCC的潜在诊断标志物。研究通过免疫沉淀结合质谱技术鉴定PLA1A为靶抗原。

2. **文献名称**：*PLA1A as a target antigen for immunotherapy in neuroblastoma*

**作者**：Yokoyama S, et al.

**摘要**：本研究证实PLA1A在神经母细胞瘤细胞中高表达，并开发了针对PLA1A的单克隆抗体，体外实验显示其可通过抗体依赖性细胞毒性(ADCC)抑制肿瘤生长。

3. **文献名称**：*Association of anti-PLA1A antibodies with infertility and recurrent miscarriage*

**作者**：Kuji N, et al.

**摘要**：研究发现反复流产患者中抗PLA1A抗体的阳性率显著升高，推测其可能通过干扰胚胎着床或胎盘形成导致妊娠失败，提示其在生殖免疫中的潜在作用。

---

注：上述文献为示例性质，实际研究中请通过PubMed或专业数据库核实具体文献信息。

背景信息

The PLA1A antibody, also known as anti-PLA1A, is an autoantibody targeting platelet glycoprotein IIIa (GPIIIa, integrin β3), a critical component of the platelet membrane involved in aggregation and clotting. Discovered in the context of immune-mediated platelet disorders, it is primarily associated with fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition where maternal antibodies cross the placenta and destroy fetal platelets. PLA1A antibodies arise when individuals lacking the human platelet antigen (HPA)-1a (PLA1A) are exposed to platelets expressing this antigen, commonly through pregnancy or transfusion. Approximately 2% of pregnancies involve HPA-1a-negative mothers carrying HPA-1a-positive fetuses, with 10-15% of these mothers developing anti-PLA1A antibodies. Severe cases may lead to intracranial hemorrhage or miscarriage. Beyond FNAIT, PLA1A antibodies are implicated in post-transfusion purpura and platelet refractoriness. Detection methods include monoclonal antibody-specific immobilization of platelet antigens (MAIPA) or bead-based immunoassays. Research continues to explore therapeutic interventions, such as intravenous immunoglobulin (IVIG) or antenatal anti-D prophylaxis, to mitigate risks. PLA1A antibody testing is crucial for prenatal screening in at-risk populations and optimizing transfusion strategies in clinical settings.

客户数据及评论

折叠内容

大包装询价

×